Jury Finds Qiagen Unit Infringed 10x Genomics Patents
QGEN sits 33% above its 52-week low of $32.53 on light trading volume (0.2× avg).
Summary
A U.S. jury found that Qiagen's Parse Biosciences unit infringed on patents held by 10x Genomics. The jury awarded $4.8 million in damages for sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The verdict exposes Qiagen to potential damages and injunctive relief, though the financial impact is not yet quantified. This is a material legal setback for Qiagen's single-cell genomics business, which competes directly with 10x Genomics. The ruling could disrupt Parse Biosciences' product sales and force licensing negotiations. Qiagen's Q2 results showed solid growth, but this litigation outcome introduces new uncertainty. Watch for post-trial motions and any damages award, which could be significant.
At the time of this announcement, QGEN was trading at $43.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.